CrownBio’s ALL and AML patient-derived xenograft (PDX) models of different leukemia subtypes are unique in the commercial world, in that they are validated, stable models with typical leukemia symp...
OmniScreen™ will be run on a cycled schedule every three months, allowing clients to select from three panels of cell lines that are most suitable for their needs.
CrownBio has made the stable cell lines available for delivery, ready to be shipped overnight for next day delivery in the United States and within one week internationally.
Under the agreement, Progenics will have use of the Selexis CHO-M Cell Line™ and the SUREtechnology Platform™ for the development, manufacture, and commercialization of Progenics’ prostate specific...
Under the agreement, Liomont will have use of the Selexis CHO-M Cell Line™ and the SUREtechnology Platform for the development, manufacture and commercialization of an undisclosed antibody.
CrownBio offers a collection large enough to be representative of the histological and genetic diversity seen in the patient population in ongoing clinical trials.
CrownBio’s newly established models have been trialed with a range of EGFR inhibitors – including I, II, and III generation TKIs as well as Erbitux® – and their poor response to therapy mirrors the...
